论文部分内容阅读
目的应用St George’s呼吸疾病问卷评分评估舒利迭(沙美特罗替卡松)治疗慢性阻塞性肺疾病(COPD)稳定期的疗效。方法选择本院及汤南中心卫生院50例COPD稳定期患者,对照组25例给予抗感染、止咳祛痰、氨茶碱、解痉平喘等常规治疗,观察组在此基础上给予吸入舒利迭(沙美特罗替卡松)50μg/250μg治疗,两组患者分别在治疗前后进行St George’s呼吸疾病问卷调查,记录评分。结果治疗组治疗前后St George’s呼吸疾病问卷评分对比有明显改善(P<0.05),但对照组无改善(P>0.05)。结论舒利迭(沙美特罗替卡松)50μg/250μg对稳定期的COPD患者有显著疗效,可以减少临床症状,提高活动能力,改善患者生活质量。
Objective To evaluate the efficacy of seretide (salmeterol and ticasone) in the treatment of patients with stable chronic obstructive pulmonary disease (COPD) using the St George’s Respiratory Disease Questionnaire. Methods Fifty patients with stable COPD in our hospital and Tangnan Central Hospital were enrolled. Twenty-five patients in the control group were given anti-infective, cough expectorant, aminophylline, antispasmodic and antiasthmatic treatments. The observation group was given inhaled Seretide (Salmeterol / fluticasone) 50μg / 250μg treatment, two groups of patients before and after treatment of St George’s respiratory disease questionnaire, record the score. Results Before and after treatment, St George’s respiratory disease questionnaire score improved significantly (P <0.05), but there was no improvement in the control group (P> 0.05). Conclusion Seretide (salmeterol / fluticasone) 50μg / 250μg has a significant effect on stable COPD patients, which can reduce clinical symptoms, improve activity ability and improve patients’ quality of life.